LeMaitre Vascular Inc (LMAT) Expected to Announce Earnings of $0.43 Per Share

Equities research analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to report earnings per share of $0.43 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for LeMaitre Vascular’s earnings. The highest EPS estimate is $0.43 and the lowest is $0.42. LeMaitre Vascular reported earnings of $0.23 per share during the same quarter last year, which indicates a positive year over year growth rate of 87%. The business is scheduled to issue its next earnings report on Thursday, July 26th.

On average, analysts expect that LeMaitre Vascular will report full-year earnings of $1.09 per share for the current financial year, with EPS estimates ranging from $1.06 to $1.11. For the next year, analysts anticipate that the business will report earnings of $1.03 per share, with EPS estimates ranging from $0.99 to $1.10. Zacks’ EPS calculations are an average based on a survey of analysts that cover LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, April 25th. The medical instruments supplier reported $0.19 EPS for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.02). The firm had revenue of $25.99 million during the quarter, compared to analysts’ expectations of $26.42 million. LeMaitre Vascular had a net margin of 17.34% and a return on equity of 16.66%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.16 EPS.

A number of research analysts recently weighed in on LMAT shares. Stifel Nicolaus lowered LeMaitre Vascular from a “buy” rating to a “hold” rating and reduced their price objective for the company from $40.00 to $34.00 in a research report on Thursday, April 26th. ValuEngine raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday, April 4th. BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. Canaccord Genuity reaffirmed a “hold” rating and set a $33.00 price objective on shares of LeMaitre Vascular in a research report on Friday, February 23rd. Finally, Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Wednesday, February 28th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. LeMaitre Vascular has an average rating of “Hold” and a consensus price target of $36.50.

Shares of LeMaitre Vascular traded up $0.36, reaching $36.98, on Thursday, according to MarketBeat. The stock had a trading volume of 106,708 shares, compared to its average volume of 150,285. The stock has a market cap of $676.13 million, a PE ratio of 43.00, a PEG ratio of 2.15 and a beta of 0.57. LeMaitre Vascular has a 12-month low of $26.37 and a 12-month high of $41.28.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 7th. Investors of record on Tuesday, May 22nd were given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date was Monday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 32.56%.

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 4,821 shares of LeMaitre Vascular stock in a transaction on Monday, June 4th. The stock was sold at an average price of $34.70, for a total value of $167,288.70. Following the completion of the sale, the chief executive officer now owns 3,086,623 shares of the company’s stock, valued at approximately $107,105,818.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 35,000 shares of LeMaitre Vascular stock in a transaction on Friday, June 1st. The stock was sold at an average price of $34.50, for a total value of $1,207,500.00. Following the completion of the sale, the chief executive officer now directly owns 3,086,623 shares of the company’s stock, valued at approximately $106,488,493.50. The disclosure for this sale can be found here. In the last three months, insiders sold 97,598 shares of company stock valued at $3,292,293. Corporate insiders own 20.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. increased its holdings in shares of LeMaitre Vascular by 73.8% in the 1st quarter. Victory Capital Management Inc. now owns 5,076 shares of the medical instruments supplier’s stock worth $184,000 after purchasing an additional 2,156 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of LeMaitre Vascular in the 1st quarter worth $215,000. Citadel Advisors LLC bought a new stake in shares of LeMaitre Vascular in the 1st quarter worth $241,000. Advisor Group Inc. increased its holdings in shares of LeMaitre Vascular by 28.3% in the 4th quarter. Advisor Group Inc. now owns 7,033 shares of the medical instruments supplier’s stock worth $223,000 after purchasing an additional 1,550 shares in the last quarter. Finally, MetLife Investment Advisors LLC bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth $244,000. 73.00% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit